Skip to Content
Merck
All Photos(2)

Documents

53541

Supelco

Tulobuterol hydrochloride

VETRANAL®, analytical standard

Synonym(s):

2-tert-Butylamino-1-(2-chlorophenyl)ethanol hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C12H18ClNO · HCl
CAS Number:
56776-01-3
Molecular Weight:
264.19
MDL number:
MFCD00214398
UNSPSC Code:
41116107
PubChem Substance ID:
329757956
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

VETRANAL®

Assay

≥98.0% (HPLC)

technique(s)

HPLC: suitable
gas chromatography (GC): suitable
solid phase extraction (SPE): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

storage temp.

2-8°C

SMILES string

Cl.CC(C)(C)NCC(O)c1ccccc1Cl

InChI

1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H

InChI key

RSLNRVYIRDVHLY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Standard for Supelco MIP SPE cartridges. For more information request Supelco Literature T407075, T706019, T706030, T706020
Tulobuterol hydrochloride is a sympathomimetic amine, possessing bronchodilator activity.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Tulobuterol hydrochloride may be used as a reference standard in determining the concentration of tulobuterol hydrochloride present in bovine liver homogenates and urine samples using gas chromatography coupled with tandem mass spectrometry (GC-MS-MS).

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK9925
BCCH6222
BCCD9390
BCCC1945
BCBX5290

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ki-Seok Kim et al.
Colloids and surfaces. B, Biointerfaces, 92, 240-245 (2011-12-30)
Porous poly(ε-caprolactone) (PCL)/Eudragit RS 100 (ERS-100) microcapsules containing tulobuterol-adsorbed silica nanotubes (S-NTs) were prepared using a solvent evaporation method. The release behaviors of the PCL/ERS-100 microcapsules were investigated as a function of S-NT content. The PCL/ERS-100 microcapsules showed a stable
Determination of tulobuterol in human plasma by capillary gas chromatography
Wood G S and Chasseaud F L.
Journal of Chromatography. B, Biomedical Sciences and Applications, 416, 154-159 (1987)
Masakazu Ichinose et al.
Respiratory medicine, 104(2), 267-274 (2009-10-31)
The current mainstream treatment for COPD is bronchodilators alone or in combination. The effects of a beta(2)-agonist, tulobuterol, administered transdermally, have been reported to last for 24h. However, there are no reports on the efficacy of tulobuterol combined with an
Shuwa Minami et al.
Internal medicine (Tokyo, Japan), 47(6), 503-509 (2008-03-18)
There is insufficient evidence for the efficacy of a transdermal tulobuterol patch (TP), although combination therapy with bronchodilators is recommended for chronic obstructive pulmonary disease (COPD). A randomized, controlled crossover study was conducted to evaluate the clinical efficacy and safety
Toshio Katsunuma et al.
Allergology international : official journal of the Japanese Society of Allergology, 62(1), 37-43 (2012-09-25)
Few studies have examined the efficacy or safety of a transdermal β(2) agonist as add-on medication to long-term leukotriene receptor antagonist (LTRA) therapy in pediatric asthma patients. In this randomized, open-label, multicenter clinical trial, children aged 4-12 years on long-term
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service